



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Brita SCHULZE *et al.*

Application No.: 09/847,538

Filed: May 3, 2001

For: CATIONIC DIAGNOSTIC, IMAGING AND
THERAPEUTIC AGENTS ASSOCIATED WITH
ACTIVATED VASCULAR SITES

Group Art Unit: 1617

Examiner: L. Wells

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

RESPONSE TO RESTRICTION REQUIREMENT


This paper responds to the Office Action (Paper 9) dated July 30, 2002, time for response to which expires August 30, 2002. In response to the species election requirement set forth in the Office Action, Applicants respectfully elect, with traverse, species (a), “particles having a zeta potential between 25-100mV”. As set forth in the Office Action, claims 1-35 are generic. Accordingly, claims 1-35 read on the elected species, “particles having a zeta potential between 25-100mV”.

If there are any additional fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time

under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP


Sally P. Teng
Reg. No. 45,397

Dated: August 29, 2002

Customer No. 09629
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, NW
Washington, D.C. 20004
(202) 739-3000